The FDA’s database for ANDA 077752 lists five oral tablet products marketed under the brand name Simvastatin. Each product is a prescription tablet with strengths of 5 mg, 10 mg, 20 mg, 40 mg, and 80 mg. All are classified as non‑reference drugs and are intended for oral administration.
A series of supplemental labeling submissions for these products have been approved. Submission numbers 9, 14, 16, 17, 18, 19, 20, 22, and 15 (partial data) received approval dates ranging from September 10 2008 to October 5 2015. All submissions are of type "SUPPL" with a labeling classification, and most are marked as standard review priority.
Regulatory UpdatesSep 3, 2026•1 min read
FDA Approves Multiple Simvastatin Tablet Labeling Submissions (ANDA 077752)
The FDA has approved several labeling submissions for generic oral Simvastatin tablets (5‑80 mg) under ANDA 077752, confirming their prescription status.
Compiled by the PharmaCountry team · Source: FDA.gov
Ratings
(0)
(0)
(0)
(0)
(0)
More articles
View all insightsResearch & Reports
Global Finished Dosage Manufacturing Landscape 2026
Oct 5, 2026
Regulatory UpdatesKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
Sep 28, 2026
AnalysisPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
Sep 28, 2026
Leave your rating